文献速递神经肿瘤

优化胶质母细胞瘤中贝伐珠单抗的剂量:少即是多

Optimizing bevacizumab dosing in glioblastoma: less is more.
PubMed 文献 · J Neurooncol · 2017-06-30

该研究回顾性分析80例接受贝伐珠单抗治疗的胶质母细胞瘤患者病历,按剂量分组比较并发症发生率。结果显示剂量低于3 mg/kg/周时无严重不良事件(≥3级),而较高剂量组发生率为21%(P<0.01),低剂量组生存期有更好趋势但未达统计学显著(中位OS 39 vs 17.3个月,P=0.07)。

要点

  • 贝伐珠单抗严重相关不良事件率为12.5%(10/80)。
  • 剂量<3 mg/kg/周组无严重不良事件(≥3级),较高剂量组发生率为21%(P<0.01)。
  • 3例归因于贝伐珠单抗的死亡均发生在较高剂量组。

核心结论

  • 使用较低剂量贝伐珠单抗时严重相关毒性发生率更低,且未削弱积极的临床影响。
  • 作者认为旨在优化贝伐珠单抗剂量的进一步工作是有依据的。

研究设计与样本

  • 回顾性分析80例接受贝伐珠单抗治疗的胶质母细胞瘤患者病历,所有患者均接受标准初始放化疗,毒性按NCI CTCAE 4.03版分级。

主要发现

  • 贝伐珠单抗严重相关不良事件率为12.5%(n=10/80)。
  • 给药剂量<3 mg/kg/周时无严重不良事件(≥3级),而接受较高剂量(≥3 mg/kg/周)者发生率为21%(P<0.01)。
  • 3例归因于贝伐珠单抗给药的患者死亡均发生在接受较高剂量的患者中。
  • 接受较低剂量的患者生存率也更好,但未达统计学显著(低剂量组中位OS 39 vs 高剂量组17.3,P=0.07)。

关键数值与推荐

  • 严重不良事件定义为≥3级(NCI CTCAE 4.03版)。
  • 低剂量组定义为<3 mg/kg/周,高剂量组定义为≥3 mg/kg/周。

临床怎么用

  • 作者认为使用较低剂量贝伐珠单抗时严重相关毒性发生率更低且未削弱积极临床影响。
  • 作者认为旨在优化贝伐珠单抗剂量的进一步工作是有依据的。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Compared to traditional chemotherapies, where dose limiting toxicities represent the maximum possible dose, monoclonal antibody therapies are used at doses well below maximum tolerated dose. However, there has been little effort to ascertain whether there is a submaximal dose at which the efficacy/complication ratio is maximized. Thus, despite the general practice of using Bevacizumab (BEV) at dosages of 10 mg/kg every other week for glioma patients, there has not been much prior work examining whether the relatively high complication rates reported with this agent can be decreased by lowering the dose without impairing efficacy. We assessed charts from 80 patients who received BEV for glioblastoma to survey the incidence of complications relative to BEV dose. All patients were treated with standard upfront chemoradiation. The toxicity was graded based on the NCI CTCAE, version 4.03. The rate of BEV serious related adverse events was 12.5% (n = 10/80). There were no serious adverse events (≥grade 3) when the administered dose was (<3 mg/kg/week), compared to a 21% incidence in those who received higher doses (≥3 mg/kg/week) (P < 0.01). Importantly, the three patient deaths attributable to BEV administration occurred in patients receiving higher doses. Patients who received lower doses also had a better survival rate, although this did not reach statistical significance [median OS 39 for low dose group vs. 17.3 for high dose group (P = 0.07)]. Lower rates of serious BEV related toxicities are noted when lower dosages are used without diminishing positive clinical impact. Further work aimed at optimizing BEV dosage is justified.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Ajlan A, Thomas P, Albakr A, et al. Optimizing bevacizumab dosing in glioblastoma: less is more. J Neurooncol. 2017. PMID: 28667595. doi:10.1007/s11060-017-2553-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。